|
Purpose : observation Liushen the therapeutic effect and mechanism of action of the anti-metastatic . Methods: Animal experiments of Lewis lung carcinoma , S180 sarcoma model, the role of efficacy observed antitumor , anti Liushen by transfer . Clinical observation Liushen of advanced non- small cell lung cancer recently objective efficacy , quality of life Karnofsky score , immune function (NK cells ) , the changes of the tumor marker CEA and toxicity reactions . Results: Animal experiments confirmed Liushen of Lewis lung carcinoma and sarcoma S180 transplanted tumors were significantly inhibited, and can significantly inhibit the growth of lung metastases , metastasis of Lewis lung carcinoma lung metastasis rate and extent were lower than the saline control group (P lt; 0.05-0.01); inhibition of tumor tissue VEGF , MMP - 2 expression and improve E calcium catenin expression , high- dose superior to low- dose , low- dose chemotherapy combined with significant synergies ; also protected immune organs of tumor-bearing mice , a tendency to reduce chemotherapy-induced immune organ damage . The clinical observation Liushen joint chemotherapy may be better to improve the clinical symptoms , stabilize and increase the weight and improve the patients quality of life , protect the body 's immune function , reduce the damage of chemotherapy on the blood system , reduce the levels of the tumor marker CEA , but reduced and stable lesions compared with chemotherapy alone group had no significant difference , compared to the two sets of damage to the liver and kidney function and digestive toxicity no statistically significant difference . Conclusion : Liushen can be used as a non- small cell lung cancer patients with an effective adjunct clinical , and play a role in the multi-level, multi-link, multi-target . The anti-metastatic mechanism : improve immune function , inhibition of tumor tissue VEGF , MMP - 2 expression , and to enhance the expression of E-cad , promote apoptosis of tumor cells .
|